| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5729730 | European Urology Focus | 2016 | 7 Pages |
Abstract
Bone Scan Index (BSI) change is related to survival time in metastatic castration-resistant prostate cancer (mCRPC) patients on abiraterone acetate. BSI may be a valuable complementary decision-making tool supporting physicians monitoring patients with mCRPC on second-line therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck-Lissbrant, Jan-Erik Damber, Anders Widmark, Camilla Thellenberg-Karlsson, Lars Budäus, Thomas Steuber, Till Eichenauer, Per Wollmer, Lars Edenbrandt, Elin TrägÃ¥rdh,